All In MedTech

Device Trial Radar · NCT00573586

Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada

Investigational Study For the Treatment of Localized (T1c/T2a) Prostate Cancer With High Intensity Focused Ultrasound (HIFU) Using the Sonablate® 500 (SB-500) System in Canada

Last checked: Nov 20, 2026Latest source record: May 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

20

Planned (sponsor's estimate)

Start

Dec 2020

Primary completion

Dec 2020

Study completion Dec 2020

Sponsor

Lead sponsor
SonaCare MedicalNot on our public-company list
Sponsor type
Industry
First posted
Dec 14, 2007

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Male only, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an investigational study on the use of high intensity focused ultrasound (HIFU) in the management of localized prostate cancer (T1c/T2a) as a primary non-comparative study. High intensity focused ultrasound (HIFU) is a non-invasive acoustic ablation technique that uses intersecting, precision focused ultrasound waves to raise the temperature of the target to) 80-90 degrees C in 2-3 seconds, destroying the targeted tissues (prostate cancer). The tissue targeting is highly precise, minimizing collateral damage. The overall hypothesis is that HIFU with Sonablate can safely, effectively and selectively ablate prostate cancer tissue, resulting in complete tissue necrosis, in patients diagnosed with localized T1c/T2a prostate cancer, with minimal morbidity. The specific hypothesis is that the Sonablate has the ability to: * Completely destroy prostate cancer tissue, without causing damage to the intervening tissue, with a drop in PSA levels to \<0.5ng/ml. * Result in negative biopsies for evidence of viable malignant cells after the treatment (12 months if Nadir is not reached or PSA rises from Nadir) * Safely treat localized prostate cancer patients, with minimal and acceptable adverse effects

Conditions

  • Prostate Cancer

Interventions

  • Sonablate 500 (SB-500)Device

    Sonablate 500 (SB-500)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PSA levelTime frame: PSA level at 30 and 90 days post treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Abbotsford Regional Hospital Cancer Center

    Abbotsford British Columbia, British Columbia, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.